Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 607Lung Neoplasms 190Neoplasms 68Neoplasm Metastasis 46Mesothelioma, Malignant 46Adenocarcinoma of Lung 42Mesothelioma 40Colorectal Neoplasms 29Carcinoma 23Breast Neoplasms 23Parkinson Disease 4, Autosomal Dominant Lewy Body 21Meningeal Carcinomatosis 20Head and Neck Neoplasms 19Brain Neoplasms 18Ovarian Neoplasms 17Adenocarcinoma 15Small Cell Lung Carcinoma 14NSCLC 14Pancreatic Neoplasms 12Melanoma 12Squamous Cell Carcinoma of Head and Neck 11Recurrence 11Lung Diseases 10Carcinoma, Transitional Cell 10Uterine Cervical Neoplasms 9Neoplasms by Site 9Adenocarcinoma, Bronchiolo-Alveolar 9Thoracic Neoplasms 8Non-squamous Non-small Cell Lung Cancer 8Carcinoma, Bronchogenic 8

Interventions

zipalertinib 1Specimen Handling 1Pemetrexed 1Magnetic Resonance Spectroscopy 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lung Non-Squamous Non-Small Cell Carcinoma × Pemetrexed × Clear all
NCT07229339 2026-02-05

Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer

Jonsson Comprehensive Cancer Center

Phase 2 Not yet recruiting
16 enrolled

Lung Non-Squamous Non-Small Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡